Wakix 4.5 mg film-coated tablets

Spain
Brand name Wakix 4.5 mg film-coated tablets
Form tablets, film-coated
Active substance / Dosage
PITOLISANT · 4.45 mg
Prescription type Hospital Diagnosis
Registration number 1151068001
Manufacturer Bioprojet Pharma
Wakix 4.5 mg film-coated tablets tablets, film-coated

Package leaflet: Information for the user

Introduction

Package leaflet: Information for the user

Wakix 4.5 mg film-coated tablets

Wakix 18 mg film-coated tablets

pitolisant

This medicinal product is subject to additional monitoring, which will allow quicker identification of new safety information. You can help by reporting any side effects you may experience. Information on how to report side effects is provided at the end of section 4.

Read this entire leaflet carefully before you start taking this medicine, because it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, consult your doctor or pharmacist.
  • This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, since it may harm them.
  • If you experience any side effects, consult your doctor or pharmacist, even if they are side effects not listed in this leaflet. See section 4.

Leaflet contents

  1. What Wakix is and what it is used for
  2. What you need to know before taking Wakix
  3. How to take Wakix
  4. Possible side effects
  5. How to store Wakix
  6. Contents of the pack and other information

1. What Wakix is and what it is used for

Wakix contains the active substance pitolisant. It is a medicine used to treat adult patients, adolescents, and children over 6 years of age with narcolepsy, with or without cataplexy.

Narcolepsy is a condition that causes excessive daytime sleepiness and a tendency to fall asleep suddenly in inappropriate situations (sleep attacks). Cataplexy usually begins with a sudden onset of muscle weakness or paralysis without loss of consciousness, occurring in response to sudden emotional reactions such as anger, fear, joy, laughter, or surprise.

The active substance, pitolisant, binds to receptors on brain cells involved in promoting wakefulness. This helps to counteract excessive daytime sleepiness and cataplexy, and to support a state of wakefulness.

2. What you need to know before taking Wakix

Do not take Wakix:

  • If you are allergic to pitolisant or to any of the other ingredients of this medicine (listed in section 6).
  • If you have severe liver problems, as pitolisant is usually broken down in the liver and its levels may become excessively high in patients with severely impaired liver function.
  • If you are breastfeeding (lactation period).

Warnings and precautions

Talk to your doctor before starting Wakix if you are in any of the following situations:

  • You have previously experienced anxiety or depression with suicidal thoughts.
  • You have liver or kidney problems, as your dose may need to be adjusted.
  • You have a stomach ulcer or are taking any medicine that may irritate the stomach (such as nonsteroidal anti-inflammatory drugs), as gastrointestinal reactions have been reported with Wakix.
  • You have obesity or anorexia, as your body weight may change (increase or decrease) while taking Wakix.
  • You have heart problems. Your doctor should regularly monitor these conditions during treatment with Wakix.
  • If you have severe epilepsy.

If you are in any of these situations, consult your doctor or pharmacist before taking Wakix.

Other issues you should discuss with your doctor or pharmacist:

Some people with psychiatric history have reported suicidal thoughts while taking this medicine. Inform your doctor immediately if you feel depressed or have suicidal thoughts (see section 4). Ask a family member or close friend to help you detect signs of depression or other changes in your behavior.

Children

Wakix must not be given to children under 6 years of age.

Use of Wakix with other medicines

Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines. Wakix may affect how other medicines work, and other medicines may affect how Wakix works. Your doctor may need to adjust the dose.

In particular, you should be cautious if taking Wakix together with certain antidepressants (e.g., imipramine, clomipramine, and mirtazapine) and certain medicines used to treat allergic conditions (antihistamines such as pheniramine maleate, chlorpheniramine, diphenhydramine, promethazine, mepyramine, and doxylamine).

Consult your doctor or pharmacist if you are taking any of the following medicines: rifampicin (antibiotic), phenytoin, carbamazepine, and phenobarbital (used mainly to control seizures), quinidine, digoxin (used to treat arrhythmia), paroxetine, fluoxetine, venlafaxine, duloxetine (antidepressants), St. John’s wort (Hypericum perforatum), a herbal medicine for depression, bupropion (antidepressant or smoking cessation aid), cinacalcet (used to treat parathyroid gland disorders), terbinafine (used to treat fungal infections), metformin, repaglinide (used to treat diabetes), docetaxel, irinotecan (used to treat cancer), cisapride (used to treat esophageal reflux), pimozide (used to treat certain mental disorders), halofantrine (used to treat malaria), efavirenz (antiviral for HIV treatment), morphine, paracetamol (used as an analgesic), dabigatran (used to treat bleeding disorders), warfarin (used to treat heart conditions), probenecid (used to treat gout and gouty arthritis). Pitolisant may be used with modafinil and sodium oxybate.

Wakix may reduce the effectiveness of hormonal contraceptives; therefore, another reliable contraceptive method should be used (see section "Pregnancy").

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Pregnancy

Wakix must not be used during pregnancy unless prescribed by your doctor. There is insufficient information available to determine specific risks associated with the use of Wakix during pregnancy. Women must use contraceptive methods during treatment with Wakix and for at least 21 days after stopping treatment. Since Wakix may reduce the effectiveness of hormonal contraceptives, another reliable contraceptive method must be used.

Breastfeeding

In animal studies, Wakix passes into breast milk. Patients taking Wakix must discontinue breastfeeding.

Driving and using machines

You should be cautious when performing activities requiring attention, such as driving or operating machinery. If you are unsure whether your condition negatively affects your ability to drive, consult your doctor.

3. How to take Wakix

Follow exactly the administration instructions for this medicine given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Adults

Treatment usually starts at a dose of 9 mg once daily and is gradually increased over three weeks to reach the most appropriate dose. At any time, your doctor may increase or reduce the dose depending on the patient's response and tolerance to the medicine.

It may take several days before the benefits of the medicine are noticeable, and maximum benefit is usually observed after several weeks of treatment.

Do not change the Wakix dosage on your own. Any change in dosage must be prescribed and supervised by your doctor.

For a dose of 4.5 mg, take one 4.5 mg tablet.

For a dose of 9 mg, take two 4.5 mg tablets.

For a dose of 18 mg, take one 18 mg tablet.

For a dose of 36 mg, take two 18 mg tablets.

Adolescents and children over 6 years of age

Treatment usually starts at a dose of 4.5 mg once daily and is gradually increased over three weeks to reach the most appropriate dose (see above).

If you weigh less than 40 kg, you must not take more than 18 mg per day.

Wakix should be taken orally once daily in the morning with breakfast.

Do not take a dose of Wakix in the afternoon, as this may cause difficulty sleeping.

If you take more Wakix than you should

If you take too many Wakix tablets, contact the nearest hospital emergency department or consult your doctor or pharmacist immediately. You may experience headache, stomach pain, nausea, or irritability. You may also have difficulty sleeping. Bring this leaflet and any remaining tablets with you.

If you forget to take Wakix

If you forget to take your dose, take the next dose at the usual time. Do not take a double dose to make up for the missed dose.

If you stop taking Wakix

You should continue taking Wakix for the duration prescribed by your doctor. Do not stop taking Wakix suddenly on your own.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everyone gets them. If you experience any side effect, consult your doctor.

Common side effects (may affect up to 1 in 10 people):

  • Difficulty sleeping, feeling anxious, feeling irritable, feeling depressed, trouble sleeping
  • Headaches, sensation of spinning (vertigo), loss of balance, tremors
  • Nausea, vomiting, indigestion
  • Tiredness (fatigue)

Uncommon side effects (may affect up to 1 in 100 people):

  • Sweating
  • Increased or decreased appetite
  • Edema
  • Feeling nervous, seeing or hearing things that are not real
  • Emotional instability
  • Abnormal dreams
  • Tension
  • Difficulty falling asleep at the beginning, middle, or end of the night, difficulty staying asleep, excessive drowsiness, drowsiness
  • State of indifference with lack of emotion
  • Nightmares
  • Feeling restless and unable to stay still
  • Panic reaction
  • Suicidal thoughts
  • Altered or increased sexual interest
  • Sudden and transient episode of muscle weakness, uncontrollable muscle spasms, or movements of one leg
  • Attention disturbance
  • Migraine
  • Epilepsy
  • Weakness
  • Lack of coordination of movement, slow body movements
  • Tingling, pins and needles, pricking, or burning sensation of the skin
  • Sudden and unpredictable phases of mobility and immobility
  • Feeling of unsteadiness
  • Decreased visual acuity, abnormal contraction or spasm of the eyelid
  • Perceiving sounds when none exist
  • Irregular heartbeat, fast or slow heart rate, increase or decrease in blood pressure, hot flush
  • Yawning
  • Dry mouth
  • Diarrhea, abdominal discomfort or pain, constipation, heartburn, stomach discomfort or pain, gastritis, excess acidity in the digestive tract
  • Itching, skin disorder where the nose and cheeks are unusually red, excessive sweating
  • Joint pain, lower back pain, muscle stiffness, muscle weakness, muscle and bone pain, pain in fingers and toes
  • Abnormal urination
  • Irregular uterine bleeding
  • Loss of strength or extreme tiredness, chest pain, malaise, edema
  • Weight gain, weight loss, abnormal electrocardiogram (ECG), abnormal blood values related to liver function

Rare side effects (may affect up to 1 in 1000 people):

  • Loss of appetite, increased appetite
  • Abnormal behavior, state of confusion, depressive state, excitability, feeling of emotional and mental uneasiness, sensation of seeing or hearing things that are not real during sleep
  • Loss of consciousness, tension headache, memory disorder, poor quality sleep
  • Abdominal discomfort, difficulty or pain when swallowing, flatulence, inflammation of the digestive tract
  • Skin infection, abnormally high sensitivity to sunlight
  • Neck pain and chest pain
  • Spontaneous abortion
  • Pain, night sweats, feeling of tightness
  • Elevated blood levels of the enzyme creatine phosphokinase, abnormal general physical condition, disturbance in the electrical recording of the heart (ECG)

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist, even if they are side effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Wakix

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the carton after EXP. The expiry date refers to the last day of the month indicated.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging once they are no longer needed. This will help protect the environment.

6. Contents of the pack and other information

Composition of Wakix

The active substance is pitolisant.

Wakix 4.5 mg tablets

Each tablet contains pitolisant hydrochloride equivalent to 4.45 mg of pitolisant.

Wakix 18 mg tablets

Each tablet contains pitolisant hydrochloride equivalent to 17.8 mg of pitolisant.

The other components are microcrystalline cellulose, crospovidone type A, talc, magnesium stearate, anhydrous colloidal silica, polyvinyl alcohol, titanium dioxide (E 171) and macrogol 3350.

Appearance of the product and contents of the pack

Wakix 4.5 mg is presented as white, film-coated, round, biconvex tablets, 3.7 mm in diameter, marked with "5" on one side.

Wakix 18 mg is presented as white, film-coated, round, biconvex tablets, 7.5 mm in diameter, marked with "20" on one side.

Wakix is supplied in bottles containing 30 or 90 tablets.

Wakix 4.5 mg: Available in packs containing 1 bottle of 30 tablets.

Wakix 18 mg: Available in packs containing 1 bottle of 30 tablets, packs containing 1 bottle of 90 tablets, or multiple packs of 90 tablets (3 bottles of 30 tablets).

Only certain pack sizes may be marketed.

Marketing Authorization Holder

Bioprojet Pharma

9, rue Rameau

75002 Paris

France

Manufacturer

Wakix 18 mg

Inpharmasci

ZI N°2 de Prouvy-Rouvignies

1 rue Nungesser

59121 Prouvy

France

Wakix 4.5 mg

Patheon

40 Boulevard de Champaret

38300 Bourgoin-Jallieu

France

More information about this medicine is available upon request by contacting the local representative of the Marketing Authorization Holder:

Belgium/Belgium/Belgium

Bioprojet Benelux

0032(0)78050202

[email protected]

Lithuania

UAB Norameda

+370 5 2306499

[email protected]

GTS Solution

+40 21 528 02 92

[email protected]

Luxembourg

Bioprojet Benelux

0032(0)78050202

[email protected]

Czech Republic

BIOXA Therapeutics (Czech) s.r.o.

+420 606 501 778

[email protected]

Hungary

UAB Norameda

+370 5 2306499

[email protected]

Denmark

Zambon Sweden, filial of Zambon Nederland B.V.

+46 (0)10 33 50 800

[email protected]

Malta

Bioprojet Pharma

0033 (0)1 47 03 66 33

[email protected]

Germany

Bioprojet Deutschland GmbH

030/3465 5460-0

[email protected]

Netherlands

Bioprojet Benelux N.V.

088 34 34 100

[email protected]

Estonia

UAB Norameda Eesti filiaal

+372 514 2118

[email protected]

Norway

Zambon Sweden, filial of Zambon Nederland B.V.

+46 (0)10 33 50 800

[email protected]

Greece

Bioprojet Pharma

0033 (0)1 47 03 66 33

[email protected]

Austria

Bioprojet Deutschland GmbH

030/3465 5460-0

[email protected]

Spain

Bioprojet Pharma

0033 (0)1 47 03 66 33

[email protected]

Poland

Norameda Polska Sp. z o.o.

+48 504 278 778

[email protected]

France

Bioprojet Pharma

0033 (0)1 47 03 66 33

[email protected]

Portugal

Ferrer Portugal, S.A

00351 214 449 600

[email protected]

Croatia

Lenis farmacevtika d.o.o.

+386 1 23 50 700

[email protected]

Ireland

Bioprojet Pharma

0033 (0)1 47 03 66 33

[email protected]

Romania

GTS Solution

+40 21 528 02 92

[email protected]

Slovenia

Lenis farmacevtika d.o.o.

+386 1 23 50 700

[email protected]

Iceland

Bioprojet Pharma

0033 (0)1 47 03 66 33

[email protected]

Slovakia

BIOXA Therapeutics s.r.o.

+421 907 927 010

[email protected]

Italy

Bioprojet Italia srl

+39 02 84254830

[email protected]

Finland

Zambon Sweden, filial of Zambon Nederland B.V.

+46 (0)10 33 50 800

[email protected]

Cyprus

Bioprojet Pharma

0033 (0)1 47 03 66 33

[email protected]

Sweden

Zambon Sweden, filial of Zambon Nederland B.V.

+46 (0)10 33 50 800

[email protected]

Latvia

Norameda parstavnieciba

+371 29272107

[email protected]

United Kingdom (Northern Ireland)

Bioprojet Pharma

0033 (0)1 47 03 66 33

[email protected]

Date of the most recent review of this leaflet:

Other sources of information

Detailed information on this medicine is available on the website of the European Medicines Agency:

http://www.ema.europa.eu.

This leaflet is available on the European Medicines Agency website in all languages of the European Union/European Economic Area.